 | |
| Clinical data | |
|---|---|
| Other names | 5-MeO-NSBT; 5-Methoxy-N-sec-butyltryptamine |
| Routes of administration | Oral [1] |
| Drug class | Psychoactive drug |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | 20–30 minutes [1] |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5-MeO-NsBT, also known as 5-methoxy-N-sec-butyltryptamine, is a psychoactive drug of the tryptamine and 5-methoxytryptamine families. [1] [2] It emerged as a novel designer drug online in December 2022. [1] More specifically, its chemical synthesis and the claimed properties and effects of 5-MeO-NsBT were posted on a specialized psychoactive drug forum. [1]
Contents
The dose of the drug is said to be 3 to 10 mg orally and its onset is said to be 20 to 30 minutes, whereas its duration was not specified. [1] Its effects were reported to include mildly increased empathy and sociability, more fluid thinking, easy and pleasant writing, intoxication, confusion, and after-effects such as mild depression. [1] In addition, possible anti-inflammatory and analgesic effects were reported. [1] No psychedelic or hallucinogenic effects were described. [1]
The drug has not otherwise been encountered, for instance sold online or in drug seizures, as of 2023. [1] It is not a controlled substance in Canada as of 2025. [3]